{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:11:40Z","timestamp":1794935500991,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gastha.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T04:47:03Z","timestamp":1731559623000},"page":"100588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3025-8643","authenticated-orcid":false,"given":"Alejandro","family":"Nieto Dominguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhurwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Mutneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Eichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu","family":"Pinnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Guifarro Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gastha.2024.11.004_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J\u00a0Inflamm Res"},{"key":"10.1016\/j.gastha.2024.11.004_bib2","series-title":"Yamada\u2019s Textbook of Gastroenterology, Seventh Edition","first-page":"1248","article-title":"Ulcerative colitis: clinical manifestations and management","author":"Singh","year":"2022"},{"key":"10.1016\/j.gastha.2024.11.004_bib3","series-title":"Clinical algorithms in general surgery","first-page":"233","article-title":"Crohn\u2019s colitis","author":"Michailidou","year":"2019"},{"issue":"7","key":"10.1016\/j.gastha.2024.11.004_bib4","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.gastha.2024.11.004_bib5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2024.11.004_bib6","first-page":"139","article-title":"Remicade\u00ae (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"issue":"9317","key":"10.1016\/j.gastha.2024.11.004_bib7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gastha.2024.11.004_bib8","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"issue":"6","key":"10.1016\/j.gastha.2024.11.004_bib9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s12325-021-01990-6","article-title":"Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era","volume":"39","author":"Schreiber","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.gastha.2024.11.004_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial","volume":"43","author":"D'Haens","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.gastha.2024.11.004_bib11","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gastha.2024.11.004_bib12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastha.2024.11.004_bib13","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"issue":"26","key":"10.1016\/j.gastha.2024.11.004_bib14","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8167","key":"10.1016\/j.gastha.2024.11.004_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A\u00a0simple index of crohn\u2019s-disease activity","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.gastha.2024.11.004_bib16","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2024.11.004_bib17","first-page":"549","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"issue":"9","key":"10.1016\/j.gastha.2024.11.004_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14341","article-title":"Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: a brief UK stakeholder survey","volume":"75","author":"Heald","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.gastha.2024.11.004_bib19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000528586","article-title":"Inflammatory bowel disease patients' preferences for subcutaneous versus intravenous therapies: a mixed-methods study","volume":"41","author":"van Deen","year":"2023","journal-title":"Dig Dis"},{"issue":"1","key":"10.1016\/j.gastha.2024.11.004_bib20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1186\/s12913-022-08683-y","article-title":"Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries","volume":"22","author":"Yoo","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"10.1016\/j.gastha.2024.11.004_bib21","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. Real clinical practice multicentre study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.gastha.2024.11.004_bib22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [ct-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"issue":"24","key":"10.1016\/j.gastha.2024.11.004_bib23","first-page":"7296","article-title":"Inflammatory bowel disease patients' acceptance for switching from intravenous infliximab or vedolizumab to subcutaneous formulation: the nancy experience","volume":"11","author":"Remy","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.gastha.2024.11.004_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2023-001105","article-title":"Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)","volume":"10","author":"Carbery","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"issue":"19","key":"10.1016\/j.gastha.2024.11.004_bib25","first-page":"5669","article-title":"Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations","volume":"11","author":"Burdge","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"Supplement_1","key":"10.1016\/j.gastha.2024.11.004_bib27","doi-asserted-by":"crossref","first-page":"i522","DOI":"10.1093\/ecco-jcc\/jjac190.0519","article-title":"Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) \u2013 a prospective, real-world, single centre, phase IV interventional study","volume":"17","author":"Rahmany","year":"2023","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.gastha.2024.11.004_bib28","doi-asserted-by":"crossref","first-page":"i837","DOI":"10.1093\/ecco-jcc\/jjac190.0835","article-title":"Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes","volume":"17","author":"Nowell","year":"2023","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.gastha.2024.11.004_bib29","doi-asserted-by":"crossref","first-page":"i920","DOI":"10.1093\/ecco-jcc\/jjac190.0917","article-title":"Subcutaneous infliximab in IBD patients with previous immunogenic failure of intravenous infliximab","volume":"17","author":"Husman","year":"2023","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"issue":"2","key":"10.1016\/j.gastha.2024.11.004_bib31","first-page":"118","article-title":"Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results","volume":"114","author":"Arg\u00fcelles-Arias","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"issue":"Supplement_1","key":"10.1016\/j.gastha.2024.11.004_bib32","doi-asserted-by":"crossref","first-page":"i161","DOI":"10.1093\/ecco-jcc\/jjac190.0126","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn\u2019s disease: a phase 3, randomised, placebo-controlled study (LIBERTY-CD)","volume":"17","author":"Colombel","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2024.11.004_bib35","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.gastha.2024.11.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2021.100063","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"3","author":"Husereau","year":"2022","journal-title":"Health Policy OPEN"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572324001845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T22:30:12Z","timestamp":1745015412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572324001845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2772572324001845"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2024.11.004","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}],"article-number":"100588"}}